SAT0408 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials

P.J Mease,C Edwards,K Shah,M Cutolo,A Kavanaugh,A.O Adebajo,E Lespessailles,G Schett,J Wollenhaupt,R Stevens,J.J Gomez-Reino,C Birbara,D Gladman,C Hu

doi:10.1136/annrheumdis-2014-eular.5589

SAT0408 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials

P.J Mease, C Edwards + Show 12 more

https://doi.org/10.1136/annrheumdis-2014-eular.5589

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2014
Citations: 4

Affiliation: University Hospital Southampton NHS Foundation Trust, University of Genoa, University of California, San Diego, University of Sheffield, University of Erlangen-Nuremberg, Schön Klinik Hamburg Eilbek, University of Massachusetts Chan Medical School, Toronto Western Hospital

#Severity Of AEs #Oral Phosphodiesterase + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

BackgroundApremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. PALACE 1, 2, and 3 compared the efficacy and safety of APR with placebo (PBO) in patients...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.